Roger J Butlin

Title: Roger J Butlin: Innovator in Pharmaceutical Chemistry

Introduction

Roger J Butlin is a notable inventor based in Manchester, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological processes. His work has implications for the treatment of various diseases, including cancer.

Latest Patents

Roger J Butlin holds a patent for "Substituted pyridines as inhibitors of DNMT1." This invention focuses on substituted pyridine derivatives, specifically compounds that are selective inhibitors of DNMT1. These compounds can be useful in treating cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia. The invention also encompasses pharmaceutical compositions that include these compounds and methods for inhibiting DNMT1 activity.

Career Highlights

Throughout his career, Roger has worked with prominent organizations, including GlaxoSmithKline Intellectual Property Development Limited and Cancer Research Technology Limited. His experience in these companies has allowed him to contribute to significant advancements in drug development and intellectual property management.

Collaborations

Roger has collaborated with notable professionals in his field, including Nicholas D Adams and Andrew B Benowitz. These collaborations have further enriched his research and development efforts.

Conclusion

Roger J Butlin's innovative work in pharmaceutical chemistry, particularly in the development of DNMT1 inhibitors, showcases his commitment to advancing medical science. His contributions have the potential to impact the treatment of serious health conditions significantly.